GlassScriptPhysician profile
Kimberly A Ashlock
NPI 1881653350
$10,819.56
in general payments reported to CMS, 2019-2025
47 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $1,147 · 2021: $1,591 · 2022: $1,482 · 2023: $1,792 · 2024: $2,044 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,530.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.21 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,464.91 | 2019-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $1,209.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,183.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $663.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $463.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.40 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $367.30 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $313.84 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.39 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $286.54 | 2019-2025 | Veozah |
| Abbott Laboratories | $273.00 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $264.88 | 2019-2025 | Otezla, Repatha, Prolia |
| Currax Pharmaceuticals LLC | $207.22 | 2020-2024 | Contrave, Nexletol, Nexlizet |
| Exact Sciences Corporation | $194.59 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ashlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.